Nigeria has not manufactured a single human vaccine since 1993, according to the National Agency for Food and Drug Administration and Control (NAFDAC). This revelation has sparked renewed interest in local vaccine production, especially as businessman Aliko Dangote pushes for domestic manufacturing. The gap highlights a long-standing reliance on imported vaccines, raising concerns about supply chain vulnerabilities and public health security.
The lack of local production has left Nigeria dependent on foreign suppliers, making it susceptible to global shortages and price fluctuations. Dangote, whose conglomerate has already begun producing essential goods like cement and food, is now exploring the pharmaceutical sector. His initiative could potentially reduce the country’s reliance on imports and boost its manufacturing capabilities.
NAFDAC’s report underscores the need for policy reforms and investment in local production. While the government has expressed interest in supporting domestic manufacturers, challenges such as regulatory hurdles and infrastructure limitations remain. The situation has gained attention amid growing calls for self-reliance in critical sectors.
The push for local vaccine production could mark a turning point for Nigeria’s pharmaceutical industry, though success will depend on sustained investment and supportive policies. (businessday.ng)
